| 23.05 07:05 | GNW-Adhoc: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders |
| 21.05 07:05 | GNW-Adhoc: Idorsia announces changes to Idorsia Executive Committee and Board of Directors |
| 21.05 06:55 | GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor |
| 21.05 06:45 | GNW-Adhoc: Idorsia announces financial results for the full year of 2023 - Adapting the company to create sustainable value |
| 14.05 17:50 | GNW-Adhoc: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call |
| 06.05 18:40 | GNW-Adhoc: Bondholders approve amended terms of the 2024 convertible bonds |
| 01.05 18:05 | GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond |
| 26.04 07:05 | GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension |
| 23.04 07:05 | GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting |
| 17.04 07:05 | GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting |
| 11.04 07:05 | GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs |
| 22.03 07:05 | GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires |
| 20.03 07:05 | GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives |
| 18.03 07:05 | GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration |
| 28.02 07:05 | GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration |
| 10.01 07:05 | GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation |
| 03.11 22:35 | GNW-Adhoc: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 |
| 24.10 07:05 | GNW-Adhoc: Idorsia gibt Finanzergebnisse für die ersten neun Monate 2023 bekannt - Anpassung des Unternehmens zur Schaffung von nachhaltigem Wert |
| 23.10 09:21 | GNW-Adhoc: Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023 |
| 17.10 17:50 | GNW-Adhoc: Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call |
|
|
